Dr. Gandara Discusses the OAK Trial for Lung Cancer

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, University of California Davis Comprehensive Cancer Center, discussed the OAK study design for patients with lung cancer.

In the OAK study, patients treated with atezolizumab (Tecentriq) who developed progressive disease could remain on the treatment if the investigator felt that they were benefitting clinically and did not have severe toxicity. This was not done with the docetaxel arm.

Over 150 patients with progressive disease continued treatment with atezolizumab and did very well, explains Gandara. The median overall survival for these patients was 12.7 months, but it is too early to determine the long-term benefits.